Ivosidenib (Tibsovo®) in combination with azacitidine. HTA ID: 23015

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 23015
Drug Ivosidenib
Brand Tibsovo®
Indication To be used in combination with azacitidine, as indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.
Assessment Process
Rapid review commissioned 08/03/2023
Rapid review completed 17/04/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivosidenib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/06/2023
Pre-submission consultation with Applicant 19/09/2023